Peridialysis Project: The Influence of Predialysis Factors on the Initial Course of Dialysis

NCT ID: NCT02488200

Last Updated: 2018-02-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-31

Study Completion Date

2020-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study plans to delineate the clinical, biochemical, sociological and psychological factors. involved in dialysis preparation, and their impact on dialysis initiation (DI), modality choice and prognosis. In particular the following questions are to be answered.

1. What factors influence unplanned DI?
2. What factors influence choice of dialysis modality?
3. What factors influence choice of dialysis access?
4. Why do physicians start dialysis?
5. What factors in the predialytic period and its immediate aftermath (the "peridialytic" period) influence prognosis?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients All patients starting active end stage renal disease (ESRD) treatment at the participating centres and their satellite centres.

No. Patients: 1000.

1. Patients who have received their recent predialysis care at another centre can be included if the previous centre's notes are available, otherwise not.
2. Patients receiving a preemptive transplant are included, even if the transplant is performed at another centre. A patient questionnaire is not required for these patients.
3. Africans are excluded (inaccurate estimated glomerular filtration rate (eGFR) calculation) Each patient is allocated a local identity number (1,2,3….). The local author keeps a registry of the true patient identity of each identity number for follow-up purposes. This registry is not to be used in any communication outside the centre.

Comment: Most patients have known chronic uremia at dialysis start. In a few cases, it is unknown whether the uremia is acute or chronic. There are two main groups:

1. Acute uremia of unknown origin. Doctors should fill the questionnaire in Table 2, which can be discarded if the patient recovers renal function within three months.
2. Acute kidney injury (AKI). Most of these patients will recover within three months, so the questionnaire can wait, and be filled in retrospectively for the few remaining patients.

Methods

1. Each participating centre fills a Centre Questionnaire, see Table 1.
2. All prescribing doctors fill in a voluntary Physician Questionnaire, see Table 4.
3. The doctor prescribing the first dialysis fills in a Motivation Questionnaire, see Table 2.
4. The local coordinator fills in a Patient Notes Review

1. Birthday
2. Sex
3. Height and weight
4. Renal diagnosis
5. Comorbidity
6. Date and creatinine at referral to nephrology dept.
7. Date and creatinine 6 months before dialysis start
8. Date and creatinine 3 months before dialysis start
9. Date and creatinine at start of dialysis information/choice
10. Date and creatinine at access prescription. Date and creatinine at access creation. If there are several attempts at access creation, the last attempt is registered. For unplanned dialysis start, this is often the same date as dialysis start.
11. Date of dialysis start
12. Following values before first dialysis: B-hemoglobin, p- creatinine, urea, potassium, calcium, phosphate, bicarbonate, albumin
13. Initial dialysis modality (centre hemodialysis (HD)/Home HD/continuous ambulatory peritoneal dialysis (CAPD)/ automated peritoneal dialysis (APD))
14. Type of start (Planned/unplanned)
15. Reason for unplanned start (primary and (if appropriate) secondary).
16. For hemodialysis patient (HD) patients, initial access (areteriovenous fisula (AVF)/arteriovenous graft (AVG) /tunneled central venous catheter (CVC)/temporary CVC)
17. Modality after 3 months (Center HD/Home HD/CAPD/APD/regained function/Transplanted/Dead)
18. Is the patient alive after 3 months Yes/No. If "No" Date of death.
19. Is the patient alive after 6 months Yes/No.
20. If "No" Date of death.Is the patient alive after 12 months Yes/No. If "No" Date of death.
21. Was the patient transplanted after inclusion? If so, when?

Responsibilities National coordinators are responsible for translation of protocol to local language, and compliance with any necessary national regulatory requirements (data protection agency, ethical committee?) Local representatives: local coordination and follow-up. Patient notes review. Additional secretarial assistance, paid or unpaid, is permitted.

Definitions

ESRD

A patient has ESRD if any of the following:

1. He receives a transplant
2. The doctor "believes" that he has ESRD at first dialysis
3. He has received \>90 days dialysis
4. If the doctor is in doubt whether the patient has acute or chronic renal failure, the patient is registered as soon as there is no doubt that the patient has ESRD For 3 \& 4, registration is performed retrospectively from the first dialysis day.

Planned dialysis

The patient's first dialysis is planned if:

1. His first hemodialysis uses an AV fistula
2. His first hemodialysis uses a permanent catheter as the patient's permanent access
3. His first peritoneal dialysis is \>6 days after catheter placement.

The patient's first dialysis is unplanned if:

1. His first hemodialysis uses a temporary catheter
2. His first hemodialysis uses a permanent catheter as the patient's temporary access (i.e. a later AV fistula is planned.
3. His first peritoneal dialysis is \<7 days after catheter placement.

Renal Diagnoses

1. Shrunken Kidneys of unknown cause
2. Glomerulonephritis
3. Chronic interstitial nephropathy, chronic pyelonephritis and postrenal uremia
4. Polycystic kidney disease
5. Hypertensive/atherosclerotic renal disease
6. Diabetic Nephropathy
7. Other

Causes of unplanned dialysis

1. Late referral
2. Acute uremia
3. Acute progression of chronic uremia
4. Doubt about reversibility
5. Clinical indication despite acceptable biochemistry
6. Fistula problems
7. Delayed planning (Controversial. I recommend dialysis planning at the latest when eGFR \<15 ml/minute. Please use your own definition).
8. Patient non-compliance
9. Patient refused dialysis, but later changed his/her mind

Causes of PD modality

1. Patient choice
2. Cardiac insufficiency
3. HD not possible

Causes of HD Modality

1. Patient Choice
2. Physically incapable of peritoneal dialysis (PD)
3. Mentally incapable of PD
4. Abdominal problems
5. Wish for Home HD
6. PD not considered

Table 1 Center Questionnaire

1. Author:
2. Centre Name:
3. Centre type: University/Non-academic
4. Approximate population covered:
5. No. new ESRD patients/year
6. How many of these

1. Preemptive transplant (%)?
2. PD (%)?
3. HD (%)?
7. What is the

1. PD prevalence (no. patients)?
2. HD prevalence?
8. How many nephrology specialists?
9. Does the department have an official policy concerning preferred initial modality:

1. No
2. PD first
3. Home HD first
4. Other (what?)
10. Does the department have an official policy concerning when pretransplant investigations should be initiated? If so what? If not, is there unofficial consensus? What?
11. Does the department have an official policy concerning when dialysis modality choice is made? If so what? If not, is there unofficial consensus? What?
12. Does the department have an official policy concerning when AV fistulae/grafts are prescribed? If so what? If not, is there unofficial consensus? What?
13. Does the department have an official policy concerning when peritoneal dialysis catheters are prescribed? If so what? If not, is there unofficial consensus? What?
14. Does the department have an official policy concerning when chronic dialysis is prescribed? If so what? If not, is there unofficial consensus? What?

Table 2. Motivation Questionnaire

You have just prescribed this patient's first dialysis. If you do not believe that the patient's dialysis requirement is chronic, you do not have to fill in this form Put a "1" besides the primary reason for starting dialysis today. Put a "2" besides a (possible) secondary reason for starting dialysis today. Put a "X" besides any other reasons that have been important in influencing your decision to prescribe dialysis today.

Taste disturbances Pulmonary stasis Social (what?) Dyspnea Practical (what?) (e.g. catheter protection) Hypertension Pericarditis Oedema Biochemical Cardiac symptoms High Plasma-Creatinine Fatigue High Urea Anorexia Low glomerular filtration rate (GFR) Nausea/vomiting High Potassium Cachexia/weight loss Acidosis Itching Low calcium Insomnia High Calcium Depression High Phosphate Diarrhea Falling GFR Other (what?)

Table 4. Physician Questionnaire What is your age? What is your sex? Are you a nephrology specialist? How many years have you been a doctor? How many years have you been a nephrology specialist?

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End Stage Renal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

No intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients starting maintenance dialysis therapies at the participating centers

Exclusion Criteria

* Africans
Minimum Eligible Age

1 Month

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Odense University Hospital

OTHER

Sponsor Role collaborator

Aarhus University Hospital Skejby

OTHER

Sponsor Role collaborator

Zealand University Hospital

OTHER

Sponsor Role collaborator

Holbaek Sygehus

OTHER

Sponsor Role collaborator

Central Jutland Regional Hospital

OTHER

Sponsor Role collaborator

Sonderborg Hospital

OTHER_GOV

Sponsor Role collaborator

Skovde Hospital

UNKNOWN

Sponsor Role collaborator

Karolinska University Hospital

OTHER

Sponsor Role collaborator

Lund University Hospital

OTHER

Sponsor Role collaborator

Turku University Hospital

OTHER_GOV

Sponsor Role collaborator

Pauls Stradins Clinical University Hospital

OTHER

Sponsor Role collaborator

Tartu University Hospital

OTHER

Sponsor Role collaborator

The Hospital of Vestfold

OTHER

Sponsor Role collaborator

St. Olavs Hospital

OTHER

Sponsor Role collaborator

Oslo University Hospital

OTHER

Sponsor Role collaborator

Herlev Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

James heaf

Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

James G Heaf, MD DMSc

Role: PRINCIPAL_INVESTIGATOR

Herlev Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Herlev Hospital

Herlev, , Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

James G Heaf, MD DMSc

Role: CONTACT

+4535125361

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

James G Heaf, MD DMSc

Role: primary

+4535125361

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRU ID 15002474

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.